# UNITED STATES
# SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

# FORM 8-K

**CURRENT REPORT**
**Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 12, 2018**

# IMPRIMIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)

| **Delaware** | **001-35814** | **45-0567010** |
|---|---|---|
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) |

| **12264 El Camino Real, Suite 350**<br>**San Diego, CA** | **92130** |
|---|---|
| (Address of principal executive offices) | (Zip Code) |

Registrant's telephone number, including area code: **(858) 704-4040**

**N/A**
(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 7.01 Regulation FD Disclosure.**

Attached as Exhibit 99.1 and 99.2 to this Item 7.01 is a presentation and fact sheet that is being used by the management of the Company at investor conferences and at meetings describing the Company.

The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 and 99.2, shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent it is specifically incorporated by reference but regardless of any general incorporation language in such filing.

The information furnished under this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed to constitute an admission that such information or exhibit is required to be furnished pursuant to Regulation FD or that such information or exhibit contains material information that is not otherwise publicly available. In addition, the Company does not assume any obligation to update such information or exhibit in the future.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

| Exhibit No. | Description |
|---|---|
| 99.1 | Imprimis Pharmaceuticals, Inc. presentation dated March 2018 |
| 99.2 | Imprimis Pharmaceuticals, Inc. fact sheet dated March 2018 |

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**IMPRIMIS PHARMACEUTICALS, INC.**

Dated: March 12, 2018

By: */s/ Andrew R. Boll*
Name: Andrew R. Boll
Title: Chief Financial Officer


imprimis
PHARMACEUTICALS
NASDAQ: IMMY
MARCH 2018

## SAFE HARBOR

This presentation contains express "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. You are cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from Imprimis Pharmaceuticals, Inc.'s (the "Company" or "Imprimis") expectations and projections. Some of these risks and uncertainties include, but are not limited to: the Company's ability to make commercially available its formulations and technologies in a timely manner or at all; market acceptance of the Company's formulations and challenges related to the marketing of the Company's formulations; its ability to obtain intellectual property protection for its assets; its ability to accurately estimate its expenses and cash burn and raise additional funds when necessary; its ability to generate profits from sales of its formulations; risks related to research and development activities; its estimates of the current and potential market size for its technologies and formulations; unexpected data, safety and technical issues; regulatory and market developments impacting compounding pharmacies, outsourcing facilities and the pharmaceutical industry; competition; and market conditions. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Reports on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. All forward-looking statements are qualified in their entirety by this cautionary statement. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Imprimis expressly disclaims any intent or obligation to update these forward-looking statements except as required by law. Our compounded formulations are not FDA approved.

# INTRODUCTION TO
# IMPRIMIS PHARMACEUTICALS

- Pharmaceutical company with 60+ composition and method patent filings
- Commercialize as compounded drugs or as candidates for FDA approval through 505(b)(2) spin-outs
- ~80% of revenue is derived from our ophthalmology formulations

imprimis PHARMACEUTICALS

**IMPRIMIS OWNS:**

**COMPOUNDING COMPANIES**

imprimis Rx

PARK COMPOUNDING

**IMPRIMIS IS THE LARGEST SHAREHOLDER OF**

**FDA 505(B)(2) COMPANIES**

eTon pharmaceuticals

surface PHARMACEUTICALS INC.

## REVENUE PERFORMANCE (IN THOUSANDS)




**15 consecutive quarters of double digit revenue growth**

**Margins expected to hit 60%**

**Decreasing Adj. EBITDA losses**

**Increasing share of business is focused on ophthalmic drugs**

| | Q1 - 2016 | Q2 - 2016 | Q3 - 2016 | Q4 - 2016 | Q1 - 2017 | Q2 - 2017 | Q3 - 2017 | Q4 - 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth y/y | 180% | 149% | 81% | 65% | 39% | 40% | 34% | 27% |
| Gross Margins | 49% | 56% | 52% | 47% | 45% | 52% | 48% | 53% |
| Adj. E(L)BITDA | (2,516) | (2,302) | (2,882) | (2,378) | (2,846) | (1,945) | (1,643) | (794) |
| % of Revs. (Ophthalmic) | 41% | 53% | 62% | 61% | 60% | 69% | 76% | 79% |


imprimis Rx
OPHTHALMOLOGY

# imprimis Rx VALUE CHAIN


**PHYSICIAN AND INSTITUTION BENEFITS**

- No insurance company, pharmacy benefit manager (PBM), wholesaler or distributor middlemen
- No formulary rejections, discount cards or rebates
- No payment submittals, investigations or PBM clawbacks
- Direct access to drug formulators to meet their needs

# OPHTHALMOLOGY MARKET DATA

| | OPPORTUNITY IN US | FY 2021 GOALS | WHERE WE ARE |
|---|---|---|---|
| **OPHTHALMIC SURGERY** | • $1 billion drug market<br>• ~4.6M ocular surgeries and other procedures[1-14]<br>• Demographic growth in the overall market ~6% per yr[15] | • 525,000 procedures<br>• 13% market share<br>• Increase revenue to >$75 per surgery by adding new products | • 400,000+ per year<br>• ~$45 per surgery<br>• Launched in 2014 |
| **GLAUCOMA** | • $2 billion drug market<br>• 19+ million targeted prescriptions[3]<br>• 4 million Americans[16] | • 600,000 annual prescription equivalents<br>• 3% prescription share<br>• $65 per monthly prescription | • Launched in Q2-2017<br>• Exceeding internal refill rate goals thus far<br>• Helped by recent addition of drug shortage formulations |
| **DRY EYE** | • $2 billion drug market<br>• 4 million prescriptions[3]<br>• Estimated 30 million Americans suffer from some form of dry eye[17] | • 400,000 annual prescription equivalents<br>• 10% prescription share<br>• $49 per monthly prescription | • Launched in Q4-2017<br>• Exceeding internal growth and refill rate goals thus far |

# FORMULATIONS FOR INDIVIDUAL PATIENTS: SIMPLE DROPS™

**PROPRIETARY FORMULATIONS INCLUDE:**

- Latanoprost (PA) – *preservative-free*
- Timolol (BB) + Latanoprost (PA)
- Timolol (BB) + brimonidine (AA) + dorzolamide (CAI)
- Timolol (BB) + brimonidine (AA) + dorzolamide (CAI) + latanoprost (PA)

- **FROM THE MEDICAL LITERATURE:**
  - Patient compliance decreases when a patient is prescribed more than one bottle[18]
  - Greater than 50% of glaucoma patients require more than one medicine[19]
  - Most FDA-approved glaucoma medications use preservatives, known to cause corneal toxicity if chronically used[20]
  - Combined fixed treatments and preservative-free topical treatments should improve adherence and quality of life by simplifying instillation and tolerance of eye drops[21]
- **SIMPLE DROPS™ UNIQUE FEATURES:**
  - Combine carbonic anhydrase inhibitors (CAI), beta blockers (BB), alpha agonists (AA) and prostaglandin analogs (PA) into one formulation
  - Contains no preservatives
  - Cost out-of-pocket is generally lower for patient[3]

# FORMULATIONS FOR INDIVIDUAL PATIENTS: TOTALTEARS™


**PROPRIETARY FORMULATIONS INCLUDE:**

| |
|---|
| Chondroitin sulfate + 0.1% cyclosporine |
| Omega-3 AR |
| Omega-3 AR/Doxycycline |
| Klarity (chondroitin sulfate + dextran) |

**FROM THE MEDICAL LITERATURE:**

- Ocular burning/stinging is a major cause of therapy discontinuation for patients using commercial 0.05% cyclosporine eye drops[22]
- Only 10% of patients stay on Rx after one year[17]
- Some commercial dry eye medications in the U.S. use preservatives, known to cause corneal toxicity if chronically used[20]

**IMPRIMIS'S 0.1% CYCLOSPORINE UNIQUE FEATURES:**

- 0.1% cyclosporine is the standard of care in Europe, Japan, and Latin America[23]
- Contains no preservatives
- Formulated with Klarity – chondroitin sulfate and dextran
- Cost out-of-pocket is generally lower for patient[3]

# FORMULATIONS FOR OFFICE USE: PHARMAPACK™


**PROPRIETARY FORMULATIONS INCLUDE:**

- Prednisolone acetate + gatifloxacin
- Prednisolone acetate + gatifloxacin + bromfenac
- Prednisolone acetate + bromfenac
- Midazolam + ketamine HCl + ondansetron

- **OCULAR SURGERY MARKET:**
  - ~4.6M ocular surgeries and other procedures annually in the U.S. [1-4]
  - Demographic growth in the overall market averages ~6% per year[4,5]
- **CHALLENGES DOCTORS FACE:**
  - Patient compliance with post procedure medications
  - Cost of drugs, often from multiple companies
  - Call backs to MD office due to medication confusion
- **PHARMAPACK™ UNIQUE FEATURES:**
  - Intellectual property creates durability of our market position
  - New formulations in 2018 to increase revenue per order/surgery
  - Enables ophthalmic physicians to use a single supplier to create a customizable PharmaPack™


OTHER IMPRIMIS BUSINESSES
eTon
pharmaceuticals
surface
PHARMACEUTICALS INC.
PARK
COMPOUNDING

eTon
pharmaceuticals

# ETON PHARMACEUTICALS, INC.
# SPIN-OUT

## WHAT IS IT?

- 505(b)(2) company with 6 pipeline drug assets
- Spun-out of Imprimis June 2017 ($20M Series A)
- Strong management team with a history of success

## WHY IS IT IMPORTANT?

- Imprimis holds passive 27% equity stake in Eton
- Mid-single digit royalty on potential sales of Imprimis contributed patent-pending drug candidates

## WHAT IS THE OPPORTUNITY?

- 3.5M shares ownership interest
- Royalty opportunity for the following candidates:
  - Synthetic corticotropin: infantile spasms
  - Injectable pentoxifylline: peyronie's disease

# SURFACE PHARMACEUTICALS, INC. SUBSIDIARY


**WHAT IS IT?**

- 505(b)(2) company with three pipeline drug assets
- Focus on ocular surface disease market (Dry Eye)
- Strong management and Board of Directors team with a history of success
- May pursue spin-off transaction similar to Eton

**WHY IS IT IMPORTANT?**

- Surface is a subsidiary of Imprimis
- Single digit royalty on potential sales of Imprimis contributed drug candidates targeting the three areas of dry eye disease: chronic, episodic and refractory

**WHAT IS THE OPPORTUNITY?**

- 3.5M common stock ownership interest in Surface by Imprimis
- Royalty opportunity for three unique drug candidates for up to five separate indications, each with a billion dollar market opportunity

PARK COMPOUNDING

# PARK COMPOUNDING, INC.
# SUBSIDIARY

21% OF Q4-2017 REVENUES


## WHAT IS IT?

- Wholly owned subsidiary
- Focused on patient-specific customized drugs
- Incubator of new drug formulation ideas from physician customers

## WHY IS IT IMPORTANT?

- Large, growing and loyal customer base
- Cash flow generating revenues
- Responsible for research and development of the drugs spun out into Eton and Surface

## WHAT IS THE OPPORTUNITY?

- Add new products and expand customer base
- Focus on higher volume and chronic care formulations
- Continue to incubate innovation

# SUMMARY

# VALUE SUMMARY

**ONE OF THE LARGEST OPHTHALMOLOGY COMPOUNDING BUSINESSES IN THE US**

- Disrupting US ophthalmic drug markets with novel compounded formulations
  - Ophthalmic Surgery $1B existing drug market
  - Glaucoma $2B+ existing drug market
  - Dry Eye $2B existing drug market
- Over 2,000 ophthalmology customers and growing

**PRODUCTS AND MARKET SHARE**

- IP focused; 60+ patents or pending patents (US & Int'l) for our formulations
- 4 years of consistent growth in ophthalmology compounding market
- Products offer unique value propositions at lower costs

**GROWTH AND PROFITABILITY**

- Strong revenue growth from new formulations expected in 2018
- Plans to significantly expand average revenue per order/surgery during 2018
- Management team focused on near term profitability
- FDA registered cGMP 503B outsourcing facility increases efficiency

**BALANCE SHEET VALUE FROM SUBSIDIARIES AND SPIN-OUTS**

- Cash flow generating subsidiary, ownership / royalty interest in two 505(b)(2) companies
  - Park Compounding: drug formulation incubator with cash flow generating revenues
  - Eton Pharma: Billion dollar market potential and a strong management team
  - Surface Pharma: Billion dollar market potential and a strong management team

# COMPANY PROFILE

| | | |
|---|---|---|
| **TRADING SYMBOL:**<br>NASDAQ: IMMY | **PRICE PER SHARE (3-5-2018):**<br>$1.99 | **STOCK PRICE RANGE (52-WEEK):**<br>$1.35 - $4.69 |
| **AVG. DAILY Q4 TRADING VOLUME:**<br>595,000 SHARES | **MARKET CAP:**<br>$41 MILLION | **SHARES OUTSTANDING:**<br>20.7 MILLION |
| **INSIDER BENEFICIAL OWNERSHIP:**<br>13%<br>*PARTICIPATION BY CEO, CFO, DIRECTOR IN DEC 2016 FINANCING | **CORPORATE HEADQUARTERS:**<br>SAN DIEGO, CA | **PRODUCTION FACILITIES:**<br>IRVINE, CA & LEDGEWOOD, NJ |

# REFERENCES AND APPENDIX

## REFERENCES


1. Market Scope, LLC, Comprehensive Report on the Global IOL Market (2013, May).
2. Number of LASIK surgeries in the United States from 1996 to 2020. Retrieved February 9, 2016 from https://www.statista.com/statistics/271478/number-of-lasik-surgeries-in-the-us/
3. Imprimis Pharmaceuticals internal business data, including IMS data, 2015-2017
4. IMV Medical Information Division, Inc. Benchmark Report MR2013 (2013, July). Retrieved December 15, 2016.
5. Endodontic Facts by the American Association of Endodontists. (n.d.). Retrieved January 07, 2017, from http://www.aae.org/about-aae/news-room/endodontic-facts.aspx
6. Friedman, J. W. (2007, September). The Prophylactic Extraction of Third Molars: A Public Health Hazard. Retrieved January 08, 2017, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1963310/
7. US Market Report Suite for Gastrointestinal Endoscopic Devices 2017 - MedSuite. (2016, August 01). Retrieved January 08, 2017, from https://www.idataresearch.com/product/us-market-report-suite-for-gastrointestinal-endoscopic-devices-2017-medsuite/
8. Allen, A. (2007). Vasectomy Risks and Benefits. Retrieved November 08, 2016, from http://www.webmd.com/men/features/vasectomy-risks-benefits
9. Elmore, J. G., MD, Longton, G. M., MS, & Carney, P. A., PhD. (2015, March 17). Diagnostic Concordance in Interpreting Breast Biopsies. Retrieved January 08, 2017, from http://jamanetwork.com/journals/jama/fullarticle/2203798
10. Voigt, J., & Mosier, M. (2013, September). A powered bone marrow biopsy system versus manual methods: a systematic review and meta-analysis of randomised trials. Retrieved January 08, 2017, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3756462/
11. Irwin, K. (2012, December 10). Prostate cancer now detectable using imaging-guided biopsy, UCLA study shows. Retrieved January 08, 2017, from http://newsroom.ucla.edu/releases/prostate-cancer-now-detectable-241575
12. Sklavos, M. M., Spracklen, C. N., Saftlas, A. F., & Pinto, L. A. (2014, February 23). Does Loop Electrosurgical Excision Procedure of the Uterine Cervix Affect Anti-Müllerian Hormone Levels? Retrieved January 08, 2017, from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3953513/
13. Centers for Disease Control and Prevention - United States, 2013. (2016, November 24). Retrieved January 07, 2017, from https://www.cdc.gov/mmwr/volumes/65/ss/ss6512a1.htm
14. ASPS 2015 Plastic Surgery Statistics Report - American Society of Plastic Surgeons. (2015). Retrieved January 8, 2017, from https://d2wirczt3b6wjm.cloudfront.net/News/Statistics/2015/plastic-surgery-statistics-full-report-2015.pdf
15. Market Scope, Steady Growth in Cataract Surgical Procedures is Expected Over the Next 5 Years, July 27, 2017, https://market-scope.com/pressrelease/steady-growth-in-cataract-surgical-procedures-is-expected-over-the-next-5-years/

## REFERENCES


16. Glaucoma Research Foundation. Glaucoma Facts and Stats. Retrieved February 9, 2017 from http://www.glaucoma.org/glaucoma/facts-statistics/glaucoma-facts-and-stats.php
17. Schott, Chris, J.P. Morgan, "'Eye' deally Positioned to Expand the Dry Eye Market . . ." August 14, 2017
18. Grover, D and Robin, A. Compliance and adherence in glaucoma management. Indian Journal of Ophthalmology 2011; 59: S93-S96
19. Fechtner, Robert, Glaucoma Today, Spring 2010. Adherence and Fixed Combination Agents, http://glaucomatoday.com/2010/04/adherence-and-fixed-combination-agents/
20. Kahook, Malik. Review of Ophthalmology. The Pros and Cons of Preservatives. April 15, 2015. https://www.reviewofophthalmology.com/article/the-pros-and-cons-of-preservatives
21. Nordmann, JP & Akesbi J. Improve adherence in glaucoma patients: a doctor's duty. June 2011. NCBI. https://www.ncbi.nlm.nih.gov/pubmed/21652110
22. PERSIST: Physician's Evaluation of Restasis Satisfaction in Second Trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective review; Mah, Francis et al. November 28, 2012 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3514052/ Retrieved on October 31, 2017
23. Mhetre, Ashwini & Shinde, Ajay. Study of Intraocular Permeability Enhancement of Brimonidine Tartrate by Formulation in Its In Situ Thermoreversible Gel. Asian Journal of Pharmaceutics. October – December 2016

# PRIMER ON COMPOUNDING SERVICES

**COMPOUNDED DRUGS FACTS:**

- When a commercial drug isn't clinically appropriate, customized drugs can be compounded by highly trained pharmaceutical chemists

  **CHALLENGE:** Down syndrome cataract surgery patient cannot administer eye drops

  **SOLUTION:** Ophthalmologist prescribes and administers a compounded combination drug consisting of the medications in the eye drops that is made as an injectable

- Used in nearly every hospital/ASC and many MD specialties and subspecialties
- Consist of bulk active drug ingredients made by FDA registered suppliers
- Strictly regulated by FDA (2013 Drug Quality & Security Act – the *DQSA*)
- The DQSA allows compounded drugs to be produced in two types of facilities:
  - *Pharmacies:* Requires an individual patient prescription (low volume)
  - *Outsourcing Facilities:* No patient prescription requirement (high volume)
- They are not FDA-approved with a label for use
- May be useful for small or large patient populations
- If novel, compounded drug formulations may be patented

# PUBLISHED CLINICAL DATA

Tyson, S. L., et al. (2017, January). Clinical outcomes after injection of a compounded pharmaceutical for prophylaxis after cataract surgery: a large-scale review. Current Opinion in Ophthalmology.
No major intraoperative complications associated with the transzonular injection technique. There were no cases of postoperative endophthalmitis. Rates of infection and inflammation reported in this retrospective review of 1,541 cases from 922 patients receiving a transzonular injection of Tri-Moxi-Vanc for prophylaxis after cataract surgery appear similar to reported rates with alternative prophylactic therapies such as topical drops.[5]

Fisher, B. L., & Potvin, R, (2016, July 18). Transzonular vitreous injection vs a single drop compounded topical pharmaceutical regimen after cataract surgery. Current Pharmaceutical Design.
Review of the rationale for reducing topical therapy in cataract surgery prophylaxis, and what is known to date about the efficacy and safety of the Dropless® approach. Both groups expressed similar satisfaction with surgery, but patients who received Dropless® preferred the overall experience (P=0.01).[4]

Lindstrom, R.L., et al. (2017, February). Dropless Cataract Surgery: An Overview. Current Pharmaceutical Design.
Compliance issues are diminished with Dropless Therapy compared to standard post-surgery topical drop regimens. Cost savings to patients can range from $200 to $600 per cataract procedure. Staff time is reduced without patient, insurance and pharmacy callbacks about eye drop substitutions and confusion over topical regimens. A retrospective review of Dropless Therapy cases found no postoperative endophthalmitis. Post- surgery infection and inflammation rates were similar to reported rates with other alternative prophylactic therapies, such as topical drops.[6]

## DRUG COMBINATION

WITHOUT SSP TECHNOLOGY®, LARGE IRREGULAR CLUMPS OF ACTIVE DRUGS PERSIST, NOT USABLE AS INJECTION OR EYE DROP


SSP TECHNOLOGY® ALLOWS FOR MIXING OF ACTIVE DRUGS INTO SUSPENSIONS FOR:
- CATARACT SURGERY
- REFRACTIVE SURGERY


imprimis
PHARMACEUTICALS
12264 EL CAMINO REAL, SUITE 350
SAN DIEGO, CA 92130
(858) 704-4040
IR@IMPRIMISPHARMA.COM
WWW.IMPRIMISRX.COM

## Investment Highlights

**Commercial pharmaceutical company focused on the three largest U.S. ophthalmic markets**

IP focused with 60+ drug formulation patents and pending patents (U.S. & Int'l)

15 consecutive quarters of double digit or better year over year revenue growth

Total Addressable Market
- Surgical $500M
- Glaucoma $500M
- Dry Eye $200M

**2021 Goal: $100M Revenue**
- Surgical: 525K procedures at $75 each = $40M
- Glaucoma: 600K Rx at $65/ month = $40M
- Dry Eye: 400K Rx at $50/ month = $20M

Addition of planned product launches and other existing revenue sources makes goal achievable

**Trading Symbol:** NASDAQ: IMMY
**Price per Share:** $1.99 (Mar. 5, '18)
**Market Cap:** $41 Million
**Shares Outstanding:** 20.7 Million
**Avg. daily Q4 volume:** 595,000 shares
**52-week price range:** $1.35 - $4.69

## What is Imprimis?

We are an ophthalmology-focused pharmaceutical company specialized in the development, production and sale of innovative medications that offer unique competitive advantages and serve unmet needs in the marketplace. Our businesses and assets are:

### ImprimisRx – core ophthalmology compounding business

We have become the leading U.S. ophthalmology focused compounding business by partnering with our 2,000 physician customers.
- Our proprietary formulations within PharmaPack™ make up 10% Rx share for perioperative ophthalmic drugs
- We recently launched Simple Drops™, which include various combinations of latanoprost, timolol, dorzolamide, and brimonidine into a single preservative-free bottle
- In 2017, we launched our patented Klarity formulations that combine chondroitin sulfate and a customized strength of cyclosporine as a preservative-free formulation

### Eton Pharmaceuticals – potential royalty interests and ~27% passive equity stake

505(b)(2) company, developing multibillion-dollar drug candidates, which may begin sales as early as 1H19. Spun out of Imprimis in June 2017, being led by a team with decades of product development experience.

### Surface Pharmaceuticals – subsidiary co., may follow a similar transaction path as Eton

505(b)(2) company focused on ocular surface diseases, including Dry Eye, with three drug candidates for up to five indications. Led by an experienced CEO with 20+ years of ophthalmology drug development experience.

### Park Compounding – wholly-owned general compounding subsidiary

Cash flow generating compounding pharmaceutical business focused on customized and proprietary drugs to meet the individual needs of patients.




| | Q1-2016 | Q2-2016 | Q3-2016 | Q4-2016 | Q1-2017 | Q2-2017 | Q3-2017 | Q4-2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue Growth | 180% | 149% | 81% | 65% | 39% | 40% | 34% | 27% |
| Gross Margin | 49% | 56% | 52% | 47% | 45% | 52% | 48% | 53% |
| Adj. E(L) BITDA | (2,516) | (2,302) | (2,882) | (2,378) | (2,846) | (1,945) | (1,643) | (794) |

www.ImprimisRx.com IR Contact: 858.704.4587 ir@imprimispharma.com

*Source material referenced is available by contacting the company.*